Cellosaurus logo
expasy logo

Cellosaurus HT-1080/hCLDN-2 (CVCL_C3V8)

[Text version]
Cell line name HT-1080/hCLDN-2
Synonyms hCLDN-2/HT1080
Accession CVCL_C3V8
Resource Identification Initiative To cite this cell line use: HT-1080/hCLDN-2 (RRID:CVCL_C3V8)
Comments Population: Caucasian.
Genetic integration: Method=Transfection/transduction; Gene=HGNC; 2041; CLDN2.
Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
Disease Fibrosarcoma (NCIt: C3043)
Fibrosarcoma (ORDO: Orphanet_2030)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0317 (HT-1080)
Sex of cell Male
Age at sampling 35Y
Category Cancer cell line
Publications

PubMed=25118216; DOI=10.1124/jpet.114.216911
Li X.-R., Iida M., Tada M., Watari A., Kawahigashi Y., Kimura Y., Yamashita T., Ishii-Watabe A., Uno T., Fukasawa M., Kuniyasu H., Yagi K., Kondoh M.
Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy.
J. Pharmacol. Exp. Ther. 351:206-213(2014)

PubMed=27713828; DOI=10.1002/prp2.266; PMCID=PMC5045943
Hashimoto Y., Kawahigashi Y., Hata T., Li X.-R., Watari A., Tada M., Ishii-Watabe A., Okada Y., Doi T., Fukasawa M., Kuniyasu H., Yagi K., Kondoh M.
Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody.
Pharmacol. Res. Perspect. 4:e00266.1-e00266.14(2016)

Cross-references
Encyclopedic resources Wikidata; Q116049507
Entry history
Entry creation15-Dec-2022
Last entry update10-Sep-2024
Version number4